To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Development of pathogenic… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method

Journal article
Authors John Clemens
Stephen Savarino
Remon Abu-Elyazeed
Mohammad Safwat
Malla Rao
Thomas Wierzba
Ann-Mari Svennerholm
Jan Holmgren
Robert Frenck
Eunsik Park
Abdollah Naficy
Published in J Infect Dis
Volume 189
Issue 12
Pages 2299-307
Publication year 2004
Published at Institute of Medical Microbiology/Immunology
Pages 2299-307
Language en
Links www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords Bacterial Toxins/metabolism, Child, Preschool, Clinical Trials/*methods, Diarrhea/microbiology/prevention & control, Egypt, Enterotoxins/metabolism, Escherichia coli/isolation & purification/metabolism/*pathogenicity, Escherichia coli Infections/microbiology/*prevention & control, *Escherichia coli Proteins, Escherichia coli Vaccines/*administration & dosage/therapeutic use, Evidence-Based Medicine, Feces/microbiology, Fimbriae Proteins/metabolism, Humans, Infant, Research Design, Treatment Outcome, Vaccines, Inactivated/*administration & dosage/therapeutic use
Subject categories Medical and Health Sciences

Abstract

BACKGROUND: To design an efficacy trial of a killed oral vaccine against enterotoxigenic Escherichia coli (ETEC) diarrhea in Egyptian children, we derived for ETEC diarrhea an empirical definition that increased the probability that diarrhea associated with excretion of ETEC was caused by the detected ETEC. METHODS: We conducted a cohort study of 397 Egyptian children <24 months old and monitored them until they were 3 years old. Vaccine-preventable (VP) ETEC was defined as ETEC expressing >/=1 of the toxin- (heat-labile [LT] toxin) and colonization-factor antigens (CFA I, II, and IV) in the vaccine. RESULTS: Although fecal excretion of VP-ETEC was highly associated with diarrhea, excretion of LT-ETEC per se was not related to diarrhea (adjusted odds ratio [OR(A)], 1.16 [95% confidence interval [CI], 0.90-1.49]). The fecal excretion of antigenic types of VP-ETEC other than LT-ETEC (non-LT VP-ETEC) was highly associated with diarrheal symptoms (OR(A), 3.91 [95% CI, 2.78-5.49]; P<.001), and this association was greater for nonbloody than for bloody diarrhea. CONCLUSIONS: Because the vaccine had been anticipated to protect primarily against symptomatic ETEC diarrhea, these results indicate that the primary-outcome definition of ETEC diarrhea for the trial should be restricted to nonbloody diarrheal episodes associated with fecal excretion of non-LT VP-ETEC.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?